In our previous studies, the most favorable outcomes were related to the cortical and early/pre-T/CD2(+) T-ALL/LBL subtypes, with a five-year OS of 69% and 48%, respectively [22,23]. The gene discussed is CD2; the disease is acute lymphoblastic leukemia.